Evidence map›Paper›PMID 42506798›Full record

ReviewPharmacy (Basel, Switzerland)2026

Factors Influencing Phenoconversion in CYP-Mediated Drug Metabolism: A Scoping Review.

Sierra Scodellaro, Stefanie Triantafilou, Iris Cohn

Abstract readReview
In one paragraph

Review in Pharmacy (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Sierra ScodellaroDivision of Clinical Pharmacology and Toxicology, Department of Pediatrics, The Hospital for Sick Children, Toronto, ON M5G 1E8, Canada.ORCID 0009-0008-5871-3085
Stefanie TriantafilouDivision of Clinical Pharmacology and Toxicology, Department of Pediatrics, The Hospital for Sick Children, Toronto, ON M5G 1E8, Canada.ORCID 0009-0002-1061-0796
Iris CohnDivision of Clinical Pharmacology and Toxicology, Department of Pediatrics, The Hospital for Sick Children, Toronto, ON M5G 1E8, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pharmacogenetics (PGx) aims to optimize drug therapy by predicting medication response based on genetic variation in drug-metabolizing enzymes. However, observed drug metabolism may differ from genotype-predicted metabolizer status given external or acquired influences. This phenomenon is known as phenoconversion. As PGx testing becomes increasingly integrated into clinical care, understanding the contributing factors of phenoconversion is important for interpreting test results and guiding treatment. This scoping review aimed to categorize reported contributors of phenoconversion affecting CYP2D6, CYP2C19, and CYP3A4 metabolism. A structured literature search was conducted across Ovid MEDLINE

Indexed as

clinical implementationdrug metabolismpharmacogeneticsphenoconversionprecision medicine

Identifiers

PMID42506798
PMCPMC13415027

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.